Monitoring new drugs. by unknown
Multi-agency cooperation
The Lisbon-based European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA) is the central
source of comprehensive information on drugs in
Europe. Its main task is to collect and disseminate
data on the use of substances controlled by the
United Nations drug conventions (1). However,
in recent years, the Centre has become increasingly
active in monitoring new substances not listed
in these conventions, but which may pose health
and social risks to our societies. Today this activity
is carried out under the terms of a specific legal
instrument adopted by the Council of the European Union in 2005.
The ‘Council Decision on the information exchange, risk assessment and control of new psychoactive
substances’ (2) allows the EU institutions and Member States to act on all new and potentially
threatening narcotic and psychotropic drugs (natural and synthetic alike) that appear on the European
drug scene. It also enhances their capacity to detect and monitor new trends. Under the terms of the
Decision, the EMCDDA and Europol, in collaboration with their respective networks and the European
Medicines Agency (EMEA), play a central role in detecting new psychoactive drugs, assessing their
characteristics and paving the way for eventual control measures.
The 2005 Council Decision broadens the scope of, and replaces, the 1997 Joint Action (3) which was
devoted exclusively to new synthetic drugs. The Decision relates to end-products and not to chemical
precursors used in the illicit manufacture of narcotic drugs and psychoactive substances (4).
Monitoring new drugs
A three-step approach
Particular dangers posed by new psychoactive
substances require ‘rapid action by the EU
Member States’, says the Council Decision. 
To facilitate this process, it sets out a three-step
approach encompassing: information
exchange/early warning, risk assessment and
decision-making.
Step 1 – Information exchange/early warning: Once a new psychoactive substance is detected on the
European drug scene, Member States ensure that information on the manufacture, traffic and use of
the drug is transmitted to the EMCDDA and Europol via the Reitox national focal points (NFPs) and
‘New psychoactive substance’: A new narcotic or
psychotropic drug, in pure form or in preparation,
that is not controlled by the 1961 United Nations
Single Convention on Narcotic Drugs or the 1971
United Nations Convention on Psychotropic
Substances, but which may pose a public health
threat comparable to that posed by substances
listed in these conventions.
(1) 1961 UN Single Convention on Narcotic Drugs; 1971 UN Convention on Psychotropic Substances.
(2) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances 
[Official Journal L 127, 20.5.2005]. 
(3) Joint action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs 
[Official Journal L 167, 25.6.1997]. http://www.emcdda.eu.int/?nnodeid=1346
(4) Council Regulation (EEC) No 3677/90 of 13 December 1990 [Official Journal L 357, 20.12.1990], last amended by Commission Regulation (EC) 
No 1232/2002 [Official Journal L 180, 10.7.2002], and Regulation (EC) 273/2004 of the European Parliament and of the Council 
of 11 February 2004 on drug precursors [Official Journal L 47, 18.2.2004, p. 1].
Definition
Step 1: Information exchange/early warning
Step 2: Risk assessment
Step 3: Decision-making
Three steps
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Europol national units (ENUs). The data are also
submitted for information to the European Commission
and the EMEA. Finally, if the EMCDDA and Europol
consider that information collected on a new
psychoactive substance merits active follow-up, 
a joint report is presented to the Council of the EU, 
the Commission and the EMEA, on the basis of which 
a decision may be taken on whether or not to launch 
a risk-assessment procedure.
Step 2 – Risk assessment: At the request of at least a
quarter of its members, or the European Commission,
the Council may decide (by majority vote) to launch a
risk-assessment procedure. The EMCDDA’s Scientific
Committee – extended by additional experts from 
the Member States, the European Commission, Europol
and the EMEA – assesses the possible health and social
risks of the newly identified drug and the implications of placing it under control. A risk-assessment
report is presented to the Commission and the Council for consideration.
Step 3 – Decision-making: At the initiative of the European Commission or a Member State, and on the
basis of the risk-assessment report, the Council may decide (by qualified majority) to adopt a decision
defining the drug to be subjected to control measures. The control measures and criminal penalties in the
EU Member States are decided in line with national laws, which in turn comply with the UN conventions.
The Council Decision does not prevent individual Member States from unilaterally introducing national
control measures they consider appropriate once a new substance has been detected.
The first EMCDDA–Europol joint report under the Council Decision (Step 1) was prepared in October
2005 on a new psychoactive substance 1-(3-chlorophenyl)piperazine (mCPP). For further details see
http://www.emcdda.eu.int/?nnodeid=1346
Previous risk assessments
Between 1997 and 2004, nine new synthetic drugs
underwent risk-assessment procedures under the Joint
Action (MBDB, 4-MTA, ketamine, GHB, PMMA, 2C-I, 
2C-T-2, 2C-T-7 and TMA-2). Of these, six substances 
(all except GHB, ketamine and MBDB) were subsequently
controlled at EU level. The related risk-assessment reports
are available in English at
http://www.emcdda.eu.int/?nnodeid=431
Broader scope: covers a wider range of substances
than the Joint Action, i.e. all new psychoactive
substances (new narcotic and psychotropic drugs)
Medicinal products: allows collection and exchange
of information (but not risk assessment or control
procedures) on authorised medicinal products used
illegitimately 
Trends: stimulates exchange of information on emerging
trends in, and new uses of, existing substances and on
possible public health-related measures 
Greater transparency: asks EMCDDA and Europol to
report annually to EU institutions on efficacy and
achievements of the system
Council Decision: What’s new?
